Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

Summary

Participation Requirements

Description

This study will evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis. All participants will receive semaglutide subcutaneously once weekly for 24 weeks, followed...

This study will evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis. All participants will receive semaglutide subcutaneously once weekly for 24 weeks, followed by 24 weeks of observation off of the study drug. IHTG will be quantified by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) evaluations at two time points during the study. Participants will attend several study visits through Week 48. Participants will complete food diaries, adherence and strength assessments, and report on hypoglycemia, vision changes, physical activity, diet, quality of life, and acceptability of study drug. Blood will be collected at all visits and stool samples at two visits. Participants must remain on their non-study-provided antiretroviral therapy (ART) throughout the study.

Tracking Information